抗磷脂综合征患者七年随访动脉粥样硬化斑块进展与糖尿病及健康对照的比较
本研究对86例血栓性抗磷脂综合征(APS)患者、86例糖尿病(DM)患者及86名年龄性别匹配的健康对照(HC)进行颈动脉和股动脉超声基线检查,并邀请参与7年随访复查。最终64例APS、58例DM和66名HC完成复查,新发斑块比例分别为51.6%、36.2%和25.8%;校正传统心血管危险因素(CVRFs)和基线斑块后,APS患者动脉粥样硬化进展风险较HC高约3倍(OR=3.07,P=0.007),较DM患者高约2倍(OR=2.25,P=0.047)。APS组多因素分析显示斑块进展与合并系统性红斑狼疮(SLE)(OR=7.78,P=0.005)及CVRFs数量(OR=3.02,P=0.002)独立相关,持续达到低密度脂蛋白目标可降低斑块进展风险(OR=0.34,P=0.021)。
要点
- 7年随访中51.6%的APS患者出现新发动脉粥样硬化斑块。
- 校正CVRFs和基线斑块后,APS患者斑块进展风险约为HC的3倍(OR=3.07,P=0.007)。
- APS合并SLE及CVRFs数量与斑块进展独立相关,持续LDL达标与较低进展风险相关。
核心结论
- 约半数APS患者在7年随访期间出现新发动脉粥样硬化斑块,风险约为健康对照的3倍。
- 合并SLE和传统CVRFs数量与APS患者斑块进展相关,支持需全面评估和控制CVRFs。
研究设计与样本
- 研究纳入86例血栓性APS患者、86例DM患者和86名年龄性别匹配的HC,均接受颈动脉和股动脉超声基线检查并被邀请参加7年随访超声复查。
- 最终64例APS患者(75%女性,43.8%为原发性APS)、58例DM患者和66名HC纳入7年超声再评估。
主要发现
- 7年随访期间新发斑块在APS、DM和HC中的比例分别为51.6%、36.2%和25.8%。
- 校正传统CVRFs和基线斑块后,APS患者动脉粥样硬化进展风险较HC高约3倍(OR=3.07,P=0.007),较DM患者高约2倍(OR=2.25,P=0.047)。
- APS组多因素分析中,校正疾病相关参数和CVRF相关药物后,斑块进展与合并SLE独立相关(OR=7.78,P=0.005),与CVRFs数量独立相关(OR=3.02,P=0.002)。
- 持续达到低密度脂蛋白目标可降低斑块进展风险(OR=0.34,P=0.021)。
临床怎么用
- 作者结论支持对APS患者进行全面CVRFs评估和控制。
- 原文未据此给出具体推荐意见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with antiphospholipid syndrome (APS) carry a substantial burden of cardiovascular disease and subclinical atherosclerosis. We aimed to assess a 7-year follow-up atherosclerotic plaque progression in APS patients versus diabetes mellitus (DM) and healthy controls (HC). METHODS: Eighty-six patients with thrombotic APS, 86 with DM and 86 HC (all age- and sex-matched) who underwent a baseline ultrasound of carotid and femoral arteries were invited for a 7-year follow-up ultrasonography examination. We compared atherosclerosis progression among the three groups and examined determinants of plaque progression in APS patients. RESULTS: Sixty-four APS patients (75% females, 43.8% with primary APS), 58 patients with DM and 66 HC were included in the 7-year ultrasound re-evaluation. New plaque was detected in 51.6%, 36.2% and 25.8% of APS, DM and HC subjects, respectively. After adjusting for traditional cardiovascular risk factors (CVRFs) and baseline plaque presence, APS patients showed a 3-fold (OR = 3.07, P = 0.007) higher risk for atherosclerosis progression versus HC and 2-fold (OR = 2.25, P = 0.047) higher risk than DM patients. In multivariate analysis in the APS group, plaque progression was independently associated with systemic lupus erythematosus (SLE) co-existence (OR = 7.78, P = 0.005) and number of CVRFs (OR = 3.02, P = 0.002), after adjusting for disease-related parameters and CVRF-related medications. Sustained low-density lipoprotein target attainment reduced plaque progression risk (OR = 0.34, P = 0.021). CONCLUSION: Half of APS patients develop new atherosclerotic plaques over a 7-year follow-up, having a three-times higher risk versus HC. Concomitant SLE and number of traditional CVRFs are associated with plaque progression, supporting the need for thorough CVRF assessment and control.
引用
- Evangelatos G, Tentolouris N, Sfikakis PP, et al. Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls. Rheumatology (Oxford). 2025. PMID: 38321577. doi:10.1093/rheumatology/keae097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。